-
1
المؤلفون: Zeng, S., Dou, W., Li, M., Zhou, Yang, 1989, Guo, J., Zhao, N., Huang, H., Zhou, Q., Hu, W., Ma, Y., Zhao, X., Xie, H.
المصدر: ChemMedChem. 15(16):1608-1617
مصطلحات موضوعية: biostability, DPP-IV, in silico testing, inhibitors, metabolism, 2 [[2 (3 aminopiperidin 1 yl) 4 oxo 6 (1h pyrazol 4 yl)thieno[3, 2 d]pyrimidin 3(4h) yl]methyl] 4 fluorobenzonitrile, 2 [[2 (3 aminopiperidin 1 yl) 4 oxo 6 (pyridin 3 yl)thieno[3, 2 [[2 (3 aminopiperidin 1 yl) 4 oxo 6 (pyridin 4 yl)thieno[3, 2 [[2 (3 aminopiperidin 1 yl) 4 oxo 6 [3 (trifluoromethyl)phenyl]thieno[3, 2 [[2 (3 aminopiperidin 1 yl) 4 oxo 7 (pyridin 3 yl)thieno[3, 2 [[2 (3 aminopiperidin 1 yl) 4 oxothieno[3, 2 [[2 (3 aminopiperidin 1 yl) 6 (2 methoxypyridin 4 yl) 4 oxothieno[3, 2 [[2 (3 aminopiperidin 1 yl) 6 (2 methylpyridin 4 yl) 4 oxothieno[3, 2 [[2 (3 aminopiperidin 1 yl) 6 (3 fluorophenyl) 4 oxothieno[3, 2 [[2 (3 aminopiperidin 1 yl) 6 (3, 5 dimethylisoxazol 4 yl) 4 oxothieno[3, 2 [[2 (3 aminopiperidin 1 yl) 6 (4 fluorophenyl) 4 oxothieno[3, 2 [[2 (3 aminopiperidin 1 yl) 6 bromo 4 oxothieno[3, 2 [[2 (3 aminopiperidin 1 yl) 6 [3 (methylsulfonyl)phenyl] 4 oxothieno[3, 2 [[2 (3 aminopiperidin 1 yl) 7 bromo 4 oxothieno[3, 2 [[2 (3 aminopiperidin 1 yl) 7 fluoro 4 oxothieno[3, 2 [[2 (3 aminopiperidin 1 yl) 7 methyl 4 oxo 6 (pyridin 3 yl)thieno[3, 2 [[2 (3 aminopiperidin 1 yl) 7 methyl 4 oxothieno[3, antidiabetic agent, cytochrome P450, dipeptidyl peptidase IV inhibitor, long acting drug, pyrimidine derivative, trelagliptin, unclassified drug, xanthine derivative, animal experiment, area under the curve, Article, computer model, controlled study, drug bioavailability, drug design, drug efficacy, drug half life, drug potency, drug transformation, glycemic control, IC50, in vitro study, in vivo study, infant, male, maximum plasma concentration, mean residence time, metabolic stability, nonhuman, priority journal, rat, time to maximum plasma concentration
وصف الملف: print